RMD / ResMed: Bulls Can Rest For Now, For Its Declining Cash Flow Performance

ResMed's (RMD) solid revenue growth in the first quarter of fiscal 2024 reflects the strength of AirSense 10 and AirSense 11 sleep devices and robust more_horizontal

ResMed Inc. (NYSE:RMD ) Q1 2024 Results Conference Call October 26, 2023 4:30 PM ET Company Participants Amy Wakeham - Chief Communications and Invest more_horizontal

Although the revenue and EPS for ResMed (RMD) give a sense of how its business performed in the quarter ended September 2023, it might be worth consid more_horizontal

ResMed's (RMD) respiratory care business continues to drive growth and the adoption of bilevel and other non-invasive ventilator solutions worldwide. more_horizontal

Investors continue to be optimistic about ResMed (RMD) due to the core business' performance and sustained growth in the SaaS business. more_horizontal

ResMed (RMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the st more_horizontal

ResMed is the global leader in the sleep apnea market. Sales growth accelerated during COVID and again recently as a result of a product recall from i more_horizontal

Some investors in ResMed, which makes machines for people with sleep apnea, think that effective new weight-loss drugs could shrink its addressable ma more_horizontal